{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:42:27Z","timestamp":1793817747840,"version":"4.6.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["22-151-37-IRG"],"award-info":[{"award-number":["22-151-37-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DE034360"],"award-info":[{"award-number":["R01DE034360"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04389-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:36Z","timestamp":1776257676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiation-induced remodeling of the T cell landscape in head and neck cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Abdullah A.","family":"Memon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imaad","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ean","family":"Norenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Foeckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumou","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Dwinell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Lochhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bruening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Akakpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyce J.","family":"Kearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaddiq J.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Himburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"4","key":"4389_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22(4):450\u2013462. https:\/\/doi.org\/10.1016\/S1470-2045(20)30737-3","journal-title":"Lancet Oncol"},{"key":"4389_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415434","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W et al (2025) Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415434","journal-title":"N Engl J Med"},{"key":"4389_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2018) Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45\u201351. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.04.008","journal-title":"Oral Oncol"},{"issue":"12","key":"4389_CR4","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J et al (2023) Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol 41(12):2166\u20132180. https:\/\/doi.org\/10.1200\/JCO.22.00332","journal-title":"J Clin Oncol"},{"issue":"6","key":"4389_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","volume":"9","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J et al (2023) Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial. JAMA Oncol 9(6):779\u2013789. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0147","journal-title":"JAMA Oncol"},{"issue":"4","key":"4389_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Souli\u00e8res D, Tahara M, de Castro G et al (2023) Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 41(4):790\u2013802. https:\/\/doi.org\/10.1200\/JCO.21.02508","journal-title":"J Clin Oncol"},{"issue":"3","key":"4389_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395996","volume":"7","author":"M Morisada","year":"2018","unstructured":"Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C et al (2018) PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 7(3):e1395996. https:\/\/doi.org\/10.1080\/2162402X.2017.1395996","journal-title":"Oncoimmunology"},{"issue":"4","key":"4389_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E et al (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3(4):345\u2013355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0196","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"4389_CR9","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR et al (2011) The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71(7):2488\u20132496. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2820","journal-title":"Cancer Res"},{"issue":"3","key":"4389_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-013-1506-7","volume":"63","author":"JY Lim","year":"2014","unstructured":"Lim JY, Gerber SA, Murphy SP, Lord EM (2014) Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63(3):259\u2013271. https:\/\/doi.org\/10.1007\/s00262-013-1506-7","journal-title":"Cancer Immunol Immunother"},{"issue":"7547","key":"4389_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373\u2013377. https:\/\/doi.org\/10.1038\/nature14292","journal-title":"Nature"},{"issue":"11","key":"4389_CR12","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD et al (2017) Integrative analysis identifies a novel AXL-PI3 Kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 23(11):2713\u20132722. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2586","journal-title":"Clin Cancer Res"},{"key":"4389_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2112","volume":"32","author":"J Bourhis","year":"2021","unstructured":"Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X et al (2021) LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann Oncol 32:S1310. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2112","journal-title":"Ann Oncol"},{"key":"4389_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2268","volume":"31","author":"J Bourhis","year":"2020","unstructured":"Bourhis J, Sire C, Tao Y, Martin L, Alfonsi M, Prevost JB et al (2020) LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 \u201cPembroRad\u201d randomized trial. Ann Oncol 31:S1168. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2268","journal-title":"Ann Oncol"},{"issue":"8","key":"4389_CR15","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR (2024) Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol 25(8):e352\u2013e362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00075-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"4389_CR16","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(19)30306-7","volume":"20","author":"SD Karam","year":"2019","unstructured":"Karam SD, Raben D (2019) Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol 20(8):e404\u2013e416. https:\/\/doi.org\/10.1016\/S1470-2045(19)30306-7","journal-title":"Lancet Oncol"},{"issue":"5","key":"4389_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11307-024-01934-w","volume":"26","author":"DF Boreel","year":"2024","unstructured":"Boreel DF, Sandker GGW, Ansems M, van den Bijgaart RJE, Peters JPW, Span PN et al (2024) MHC-I and PD-L1 expression is associated with decreased tumor outgrowth and is radiotherapy-inducible in the murine head and neck squamous cell carcinoma model MOC1. Mol Imaging Biol 26(5):835\u2013846. https:\/\/doi.org\/10.1007\/s11307-024-01934-w","journal-title":"Mol Imaging Biol"},{"key":"4389_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"issue":"47","key":"4389_CR19","doi-asserted-by":"publisher","first-page":"18490","DOI":"10.1073\/pnas.0809242105","volume":"105","author":"RR Weichselbaum","year":"2008","unstructured":"Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N et al (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105(47):18490\u201318495. https:\/\/doi.org\/10.1073\/pnas.0809242105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4389_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.3563","author":"AA Memon","year":"2025","unstructured":"Memon AA, Awan MJ, Espinosa OV, Kuehn R, Frei A, Foeckler J et al (2025) Multiomic selection of Cancer-Testis antigens as precision immuno-oncologic targets in head and neck cancer. JAMA Otolaryngol Head Neck Surg. https:\/\/doi.org\/10.1001\/jamaoto.2025.3563","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"4389_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.radonc.2022.01.003","volume":"168","author":"D Dai","year":"2022","unstructured":"Dai D, Tian Q, Shui Y, Li J, Wei Q (2022) The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis. Radiother Oncol 168:28\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.003","journal-title":"Radiother Oncol"},{"issue":"12","key":"4389_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/hed.23535","volume":"36","author":"JL Campian","year":"2014","unstructured":"Campian JL, Sarai G, Ye X, Marur S, Grossman SA (2014) Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 36(12):1747\u20131753. https:\/\/doi.org\/10.1002\/hed.23535","journal-title":"Head Neck"},{"issue":"2","key":"4389_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2015.10.029","volume":"118","author":"H Moon","year":"2016","unstructured":"Moon H, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY et al (2016) Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy. Radiother Oncol 118(2):330\u2013334. https:\/\/doi.org\/10.1016\/j.radonc.2015.10.029","journal-title":"Radiother Oncol"},{"key":"4389_CR24","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ac16ea","author":"J Shin","year":"2021","unstructured":"Shin J, Xing S, McCullum L, Hammi A, Pursley J, Correa CA et al (2021) HEDOS-a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations. Phys Med Biol. https:\/\/doi.org\/10.1088\/1361-6560\/ac16ea","journal-title":"Phys Med Biol"},{"key":"4389_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1066255","volume":"14","author":"J Qiu","year":"2023","unstructured":"Qiu J, Lin H, Ke D, Yu Y, Xu J, Qiu H et al (2023) Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol 14:1066255. https:\/\/doi.org\/10.3389\/fimmu.2023.1066255","journal-title":"Front Immunol"},{"key":"4389_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110030","volume":"190","author":"C Friedes","year":"2024","unstructured":"Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A et al (2024) The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol 190:110030. https:\/\/doi.org\/10.1016\/j.radonc.2023.110030","journal-title":"Radiother Oncol"},{"key":"4389_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111122","volume":"212","author":"HS Penzl","year":"2025","unstructured":"Penzl HS, Ziegler DA, Schirmer MA, Bensberg J, Ziegler S, Kieslich B et al (2025) Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC). Radiother Oncol 212:111122. https:\/\/doi.org\/10.1016\/j.radonc.2025.111122","journal-title":"Radiother Oncol"},{"issue":"1","key":"4389_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/jrr\/rraf087","volume":"67","author":"S Ha","year":"2026","unstructured":"Ha S, Lee TH, Chie EK, Son J, Choi CH, Kang HC et al (2026) Blood dose estimates in radiotherapy and correlations with adverse clinical outcomes in hepatocellular carcinoma. J Radiat Res 67(1):148\u2013157. https:\/\/doi.org\/10.1093\/jrr\/rraf087","journal-title":"J Radiat Res"},{"issue":"19","key":"4389_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.18632\/oncotarget.27564","volume":"11","author":"V Kapoor","year":"2020","unstructured":"Kapoor V, Collins A, Griffith K, Ghosh S, Wong N, Wang X et al (2020) Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow. Oncotarget 11(19):1681\u20131690. https:\/\/doi.org\/10.18632\/oncotarget.27564","journal-title":"Oncotarget"},{"key":"4389_CR30","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.clon.2025.103873","volume":"44","author":"TA Mickel","year":"2025","unstructured":"Mickel TA, Moon DH, Avkshtol V, Pham NL, Shah JL, Hughes RS et al (2025) Relationship between elective neck irradiation and severe lymphopenia in patients treated with head and neck chemoradiotherapy. Clin Oncol (R Coll Radiol) 44:103873. https:\/\/doi.org\/10.1016\/j.clon.2025.103873","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"4389_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60827-w","volume":"16","author":"J Zenga","year":"2025","unstructured":"Zenga J, Awan MJ, Frei A, Foeckler J, Kuehn R, Kasprzak J et al (2025) Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer. Nat Commun 16(1):5660. https:\/\/doi.org\/10.1038\/s41467-025-60827-w","journal-title":"Nat Commun"},{"issue":"6","key":"4389_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101054","volume":"4","author":"WH Hudson","year":"2023","unstructured":"Hudson WH, Olson JJ, Sudmeier LJ (2023) Immune microenvironment remodeling after radiation of a progressing brain metastasis. Cell Rep Med 4(6):101054. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101054","journal-title":"Cell Rep Med"},{"key":"4389_CR33","doi-asserted-by":"publisher","first-page":"1414298","DOI":"10.3389\/fimmu.2024.1414298","volume":"15","author":"J Kirchner","year":"2024","unstructured":"Kirchner J, Plesca I, Rothe R, Resag A, Lock S, Benesova I et al (2024) Type I conventional dendritic cells and CD8(+) T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients. Front Immunol 15:1414298. https:\/\/doi.org\/10.3389\/fimmu.2024.1414298","journal-title":"Front Immunol"},{"issue":"1","key":"4389_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR et al (2021) B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun 12(1):3349. https:\/\/doi.org\/10.1038\/s41467-021-23355-x","journal-title":"Nat Commun"},{"issue":"7791","key":"4389_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561\u2013565. https:\/\/doi.org\/10.1038\/s41586-019-1914-8","journal-title":"Nature"},{"key":"4389_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2018.00256","volume":"8","author":"G Boivin","year":"2018","unstructured":"Boivin G, Kalambaden P, Faget J, Rusakiewicz S, Montay-Gruel P, Meylan E et al (2018) Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy. Front Oncol 8:256. https:\/\/doi.org\/10.3389\/fonc.2018.00256","journal-title":"Front Oncol"},{"issue":"1","key":"4389_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic I, Yong CSM, Kurz L, Vetrugno I, Reichl S, Fernandez AS et al (2024) Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat Commun 15(1):5500. https:\/\/doi.org\/10.1038\/s41467-024-49873-y","journal-title":"Nat Commun"},{"issue":"1","key":"4389_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61780-4","volume":"16","author":"R Saddawi-Konefka","year":"2025","unstructured":"Saddawi-Konefka R, Msari RA, Tang S, Philips C, Sadat S, Clubb LM et al (2025) The tumor-sentinel lymph node immuno-migratome reveals CCR7\u207a dendritic cells drive response to sequenced immunoradiotherapy. Nat Commun 16(1):6578. https:\/\/doi.org\/10.1038\/s41467-025-61780-4","journal-title":"Nat Commun"},{"issue":"1","key":"4389_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA et al (2022) Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun 13(1):7015. https:\/\/doi.org\/10.1038\/s41467-022-34676-w","journal-title":"Nat Commun"},{"issue":"20","key":"4389_CR40","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ et al (2018) Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res 24(20):5058\u20135071. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3427","journal-title":"Clin Cancer Res"},{"key":"4389_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001955","author":"MW Knitz","year":"2021","unstructured":"Knitz MW, Bickett TE, Darragh LB, Oweida AJ, Bhatia S, Van Court B et al (2021) Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001955","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4389_CR42","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","volume":"3","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A et al (2022) A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer 3(11):1300\u20131317. https:\/\/doi.org\/10.1038\/s43018-022-00450-6","journal-title":"Nat Cancer"},{"issue":"64","key":"4389_CR43","doi-asserted-by":"publisher","first-page":"eabg7836","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I et al (2021) A reservoir of stem-like CD8. Sci Immunol 6(64):eabg7836. https:\/\/doi.org\/10.1126\/sciimmunol.abg7836","journal-title":"Sci Immunol"},{"key":"4389_CR44","doi-asserted-by":"crossref","unstructured":"Bahig H ea, (2023 )editor Phase I\/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results. American Society of Clinical Oncology. Journal of Clinical Oncology","DOI":"10.1200\/JCO.2023.41.16_suppl.6050"},{"issue":"12","key":"4389_CR45","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845\u20131851. https:\/\/doi.org\/10.1038\/s41591-018-0232-2","journal-title":"Nat Med"},{"issue":"1","key":"4389_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","volume":"17","author":"CM Bestvina","year":"2022","unstructured":"Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ et al (2022) A Phase 1 trial of concurrent or sequential Ipilimumab, Nivolumab, and stereotactic body radiotherapy in patients with Stage IV NSCLC study. J Thorac Oncol 17(1):130\u2013140. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4389_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J et al (2021) Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol 39(1):30\u201337. https:\/\/doi.org\/10.1200\/JCO.20.00290","journal-title":"J Clin Oncol"},{"key":"4389_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01018-w","author":"J Huang","year":"2025","unstructured":"Huang J, Theelen WSME, Belcaid Z, Najjar M, van der Geest D, Singh D et al (2025) Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-025-01018-w","journal-title":"Nat Cancer"},{"issue":"23","key":"4389_CR49","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/JCO-24-01580","volume":"43","author":"DP Zandberg","year":"2025","unstructured":"Zandberg DP, Vujanovic L, Clump DA, Isett BP, Wang H, Sica G et al (2025) Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer. J Clin Oncol 43(23):2572\u20132582. https:\/\/doi.org\/10.1200\/JCO-24-01580","journal-title":"J Clin Oncol"},{"key":"4389_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","author":"J Bourhis","year":"2025","unstructured":"Bourhis J, Auperin A, Borel C, Lefebvre G, Racadot S, Geoffrois L et al (2025) NIVOPOSTOP (GORTEC 2018\u201301): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA2","journal-title":"J Clin Oncol"},{"issue":"17","key":"4389_CR51","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15(17):5379\u20135388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0265","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4389_CR52","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy versus pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol 5(9):1276\u20131282. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478","journal-title":"JAMA Oncol"},{"issue":"5","key":"4389_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X","journal-title":"Lancet Respir Med"},{"issue":"9","key":"4389_CR54","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F et al (2023) Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS Phase 2 randomized clinical trial. JAMA Oncol 9(9):1205\u20131213. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2132","journal-title":"JAMA Oncol"},{"issue":"5","key":"4389_CR55","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5):1259\u20131271. https:\/\/doi.org\/10.1084\/jem.20052494","journal-title":"J Exp Med"},{"key":"4389_CR56","doi-asserted-by":"publisher","unstructured":"Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW (2014) Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure resulting in enhanced T-cell killing. Oncotarget 5(2): 403\u201316 https:\/\/doi.org\/10.18632\/oncotarget.1719","DOI":"10.18632\/oncotarget.1719"},{"issue":"1","key":"4389_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523","journal-title":"Nat Med"},{"issue":"5","key":"4389_CR58","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41(5):843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019","journal-title":"Immunity"},{"issue":"1","key":"4389_CR59","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1038\/s41598-020-64408-3","volume":"10","author":"LK Zebertavage","year":"2020","unstructured":"Zebertavage LK, Alice A, Crittenden MR, Gough MJ (2020) Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity. Sci Rep 10(1):7376. https:\/\/doi.org\/10.1038\/s41598-020-64408-3","journal-title":"Sci Rep"},{"issue":"92","key":"4389_CR60","doi-asserted-by":"publisher","first-page":"eadj3945","DOI":"10.1126\/sciimmunol.adj3945","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Li S, Wang M, Wang X, Chen S, Sun Z et al (2024) STING licensing of type I dendritic cells potentiates antitumor immunity. Sci Immunol 9(92):eadj3945. https:\/\/doi.org\/10.1126\/sciimmunol.adj3945","journal-title":"Sci Immunol"},{"issue":"11","key":"4389_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100410","volume":"21","author":"A Tailor","year":"2022","unstructured":"Tailor A, Estephan H, Parker R, Woodhouse I, Abdulghani M, Nicastri A et al (2022) Ionizing radiation drives key regulators of antigen presentation and a global expansion of the immunopeptidome. Mol Cell Proteomics 21(11):100410. https:\/\/doi.org\/10.1016\/j.mcpro.2022.100410","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"4389_CR62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4049\/jimmunol.2100793","volume":"211","author":"MH Lee","year":"2023","unstructured":"Lee MH, Ratanachan D, Wang Z, Hack J, Adbulrahman L, Shamlin NP et al (2023) Adaptation of the tumor antigen presentation machinery to ionizing radiation. J Immunol 211(4):693\u2013705. https:\/\/doi.org\/10.4049\/jimmunol.2100793","journal-title":"J Immunol"},{"key":"4389_CR63","doi-asserted-by":"publisher","unstructured":"Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, et al. (2021) Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 118(24) https:\/\/doi.org\/10.1073\/pnas.2102611118","DOI":"10.1073\/pnas.2102611118"},{"issue":"1","key":"4389_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0609-x","volume":"7","author":"S Park","year":"2019","unstructured":"Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D et al (2019) Paired whole exome and transcriptome analyses for the immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. J Immunother Cancer 7(1):128. https:\/\/doi.org\/10.1186\/s40425-019-0609-x","journal-title":"J Immunother Cancer"},{"issue":"38","key":"4389_CR65","doi-asserted-by":"publisher","first-page":"23721","DOI":"10.1073\/pnas.2001933117","volume":"117","author":"J Chow","year":"2020","unstructured":"Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB (2020) Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc Natl Acad Sci U S A 117(38):23721\u201323729. https:\/\/doi.org\/10.1073\/pnas.2001933117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4389_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006392","author":"J Chow","year":"2023","unstructured":"Chow J, Khan A, Gaudieri M, Wasik BJ, Conway A, Soh KT et al (2023) Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006392","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4389_CR67","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijrobp.2024.08.008","volume":"121","author":"SF Shaitelman","year":"2025","unstructured":"Shaitelman SF, Le-Petross H, Raso MG, Swanson DM, Schalck AP, Contreras A et al (2025) PRECISE: Preoperative radiation therapy to elicit critical immune stimulating effects-a phase 2 clinical trial. Int J Radiat Oncol Biol Phys 121(1):90\u201396. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"4389_CR68","first-page":"5150","volume":"56","author":"D Hallahan","year":"1996","unstructured":"Hallahan D, Kuchibhotla J, Wyble C (1996) Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 56(22):5150\u20135155","journal-title":"Cancer Res"},{"issue":"3","key":"4389_CR69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1667\/rr2773.1","volume":"177","author":"HJ Park","year":"2012","unstructured":"Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311\u2013327. https:\/\/doi.org\/10.1667\/rr2773.1","journal-title":"Radiat Res"},{"issue":"1","key":"4389_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","volume":"77","author":"M Nordsmark","year":"2005","unstructured":"Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. an international multi-center study. Radiother Oncol 77(1):18\u201324. https:\/\/doi.org\/10.1016\/j.radonc.2005.06.038","journal-title":"Radiother Oncol"},{"issue":"2","key":"4389_CR71","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ijrobp.2010.12.068","volume":"82","author":"SE Finkelstein","year":"2012","unstructured":"Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J et al (2012) Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys 82(2):924\u2013932. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.12.068","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4389_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002088","author":"DP Zandberg","year":"2021","unstructured":"Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A et al (2021) Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-002088","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4389_CR73","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.4049\/jimmunol.1201371","volume":"189","author":"RJ Cummings","year":"2012","unstructured":"Cummings RJ, Gerber SA, Judge JL, Ryan JL, Pentland AP, Lord EM (2012) Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism. J Immunol 189(9):4247\u20134257. https:\/\/doi.org\/10.4049\/jimmunol.1201371","journal-title":"J Immunol"},{"key":"4389_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189153","author":"H Nisar","year":"2025","unstructured":"Nisar H, Konda B, Hoffmann MD, Labonte FM, Arif M, Diegeler S et al (2025) Effect of reoxygenation on radioresistance of chronically hypoxic A549 non-small cell lung cancer (NSCLC) cells following X-Ray and carbon ion exposure. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26189153","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4389_CR75","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/mp.12194","volume":"44","author":"M Guerrero","year":"2017","unstructured":"Guerrero M, Carlson DJ (2017) A radiobiological model of reoxygenation and fractionation effects. Med Phys 44(5):2002\u20132010. https:\/\/doi.org\/10.1002\/mp.12194","journal-title":"Med Phys"},{"issue":"4","key":"4389_CR76","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1667\/RR3116.1","volume":"179","author":"J Lan","year":"2013","unstructured":"Lan J, Wan XL, Deng L, Xue JX, Wang LS, Meng MB et al (2013) Ablative hypofractionated radiotherapy normalizes tumor vasculature in Lewis lung carcinoma mice model. Radiat Res 179(4):458\u2013464. https:\/\/doi.org\/10.1667\/RR3116.1","journal-title":"Radiat Res"},{"issue":"11","key":"4389_CR77","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P et al (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439\u20132453. https:\/\/doi.org\/10.1084\/jem.20100587","journal-title":"J Exp Med"},{"issue":"680","key":"4389_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","volume":"15","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E et al (2023) Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med 15(680):eabn6758. https:\/\/doi.org\/10.1126\/scitranslmed.abn6758","journal-title":"Sci Transl Med"},{"issue":"6","key":"4389_CR79","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1002\/mp.17829","volume":"52","author":"J Li","year":"2025","unstructured":"Li J, Mali R, Gan GN, Lominska C, Guida K, Juloori A et al (2025) Patient-specific modeling of radiation-induced lymphopenia for head and neck cancer. Med Phys 52(6):3583\u20133594. https:\/\/doi.org\/10.1002\/mp.17829","journal-title":"Med Phys"},{"issue":"4","key":"4389_CR80","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v17.i4.105722","volume":"17","author":"XX Yang","year":"2025","unstructured":"Yang XX, Luo H, Zhang JJ, Ge H, Ge L (2025) Clinical translation of ultra-high dose rate flash radiotherapy: opportunities, challenges, and prospects. World J Radiol 17(4):105722. https:\/\/doi.org\/10.4329\/wjr.v17.i4.105722","journal-title":"World J Radiol"},{"issue":"23","key":"4389_CR81","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO-24-02194","volume":"43","author":"S van den Bosch","year":"2025","unstructured":"van den Bosch S, Doornaert PAH, Hoebers FJP, Kreike B, Vergeer MR, Zwijnenburg EM et al (2025) Clinical benefit and safety of reduced elective dose in definitive radiotherapy for head and neck squamous cell carcinoma: the UPGRADE-RT multicenter randomized controlled trial. J Clin Oncol 43(23):2583\u20132594. https:\/\/doi.org\/10.1200\/JCO-24-02194","journal-title":"J Clin Oncol"},{"key":"4389_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.013","author":"JC Osorio","year":"2025","unstructured":"Osorio JC, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M et al (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.013","journal-title":"Cancer Cell"},{"issue":"72","key":"4389_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC Hsieh","year":"2022","unstructured":"Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M et al (2022) ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72):eabl9330. https:\/\/doi.org\/10.1126\/sciimmunol.abl9330","journal-title":"Sci Immunol"},{"issue":"1","key":"4389_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23442-z","volume":"12","author":"Z Bian","year":"2021","unstructured":"Bian Z, Shi L, Kidder K, Zen K, Garnett-Benson C, Liu Y (2021) Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat Commun 12(1):3229. https:\/\/doi.org\/10.1038\/s41467-021-23442-z","journal-title":"Nat Commun"},{"issue":"11","key":"4389_CR85","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(21)00271-4","volume":"8","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR et al (2021) Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study. Lancet Haematol 8(11):e808\u2013e817. https:\/\/doi.org\/10.1016\/S2352-3026(21)00271-4","journal-title":"Lancet Haematol"},{"key":"4389_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122470","volume":"305","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Q, Yan Y, Hao Y, Wang C, Liu B et al (2024) Gel-mediated recruitment of conventional type 1 dendritic cells potentiates the therapeutic effects of radiotherapy. Biomaterials 305:122470. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122470","journal-title":"Biomaterials"},{"issue":"12","key":"4389_CR87","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/ijc.34874","volume":"154","author":"M Kamei","year":"2024","unstructured":"Kamei M, Matsuo K, Yoshida Y, Shimada K, Otsuki M, Fujimoto N et al (2024) Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. Int J Cancer 154(12):2176\u20132188. https:\/\/doi.org\/10.1002\/ijc.34874","journal-title":"Int J Cancer"},{"issue":"5","key":"4389_CR88","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00262-022-03313-2","volume":"72","author":"C Rutihinda","year":"2023","unstructured":"Rutihinda C, Haroun R, Saidi NE, Ordo\u00f1ez JP, Naasri S, L\u00e9vesque D et al (2023) Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy. Cancer Immunol Immunother 72(5):1089\u20131102. https:\/\/doi.org\/10.1007\/s00262-022-03313-2","journal-title":"Cancer Immunol Immunother"},{"key":"4389_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113521","volume":"198","author":"Y Chiang","year":"2024","unstructured":"Chiang Y, Lu LF, Tsai CL, Tsai YC, Wang CC, Hsueh FJ et al (2024) C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation. Eur J Cancer 198:113521. https:\/\/doi.org\/10.1016\/j.ejca.2023.113521","journal-title":"Eur J Cancer"},{"key":"4389_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1662216","volume":"16","author":"C Frank","year":"2025","unstructured":"Frank C, Xiao Z, Allen KJH, Jiao R, Malo ME, Dadachova E (2025) (225)Actinium-armed antibody targeting CCR8(+) regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models. Front Immunol 16:1662216. https:\/\/doi.org\/10.3389\/fimmu.2025.1662216","journal-title":"Front Immunol"},{"issue":"7738","key":"4389_CR91","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234\u2013239. https:\/\/doi.org\/10.1038\/s41586-018-0792-9","journal-title":"Nature"},{"key":"4389_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1538032","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Hu YF, Ma L, Wu Y, Chao D, Chen X et al (2025) A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. Front Immunol 16:1538032. https:\/\/doi.org\/10.3389\/fimmu.2025.1538032","journal-title":"Front Immunol"},{"issue":"2 Pt 1","key":"4389_CR93","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP et al (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11(2 Pt 1):728\u2013734","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4389_CR94","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","volume":"76","author":"ME Rodriguez-Ruiz","year":"2016","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL et al (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76(20):5994\u20136005. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0549","journal-title":"Cancer Res"},{"issue":"2","key":"4389_CR95","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ijrobp.2021.05.014","volume":"111","author":"J Sia","year":"2021","unstructured":"Sia J, Hagekyriakou J, Chindris I, Albarakati H, Leong T, Schlenker R et al (2021) Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses. Int J Radiat Oncol Biol Phys 111(2):502\u2013514. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4389_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217935","volume":"631","author":"C Wang","year":"2025","unstructured":"Wang C, Han L, Zhang J, Ji Q, Guo X, Li Y et al (2025) Radiotherapy in combination with PD-1 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8(+) T cells. Cancer Lett 631:217935. https:\/\/doi.org\/10.1016\/j.canlet.2025.217935","journal-title":"Cancer Lett"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04389-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04389-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04389-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:39Z","timestamp":1776257679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04389-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4389"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04389-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval was obtained or needed given this article is a review paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consent was obtained or needed given this article is a review paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"148"}}